The next revolution in precision oncology

Pangea Biomed is an RNA-focused precision oncology biotech company on a mission to redefine cancer care.

This will be achieved by significantly accelerating drug discovery and development, charting a highly personalized treatment course for each patient, and improving clinical efficiency and outcomes.

Solution

Pangea is redefining precision oncology and increasing the number of patients who can benefit from it.

Immunotherapy and precision oncology have been around for decades, providing hope for those with cancer, but less than 10 percent of cancer patients benefit from today’s treatments.

By coupling the hidden power of RNA sequencing with ML-enabled network effects, our ENLIGHT platform can surface relevant biological insights to pinpoint the best path forward toward combating a patient’s cancer.

Our Platform

The world’s most advanced multi-cancer response predictor

Meet ENLIGHT – Pangea’s proprietary platform offering response prediction for dozens of cancer types and more than a hundred oncology drugs.

ENLIGHT uses network effects and RNA-sequencing to identify and observe gene group interactions to determine a patient’s best treatment match.

The platform’s accuracy and efficacy have been demonstrated by published evidence and proven successful for patients who would otherwise not qualify for precision cancer care.

Improving oncology drug development

Expanding indications for existing drugs

Increasing patient benefits from precision oncology by 5X

Identifying novel drug targets

Matching patients with the right drugs and therapies at scale

Product

ENLIGHT|Lens: AI-driven precision drug development

  •  
  • ENLIGHT|Lens can surface relevant biological insights to pinpoint the best path toward combating a patient’s cancer. It interprets tumor RNA data alongside genomic data to identify treatment opportunities for each tumor.
  •  
  • Unsupervised machine learning techniques are used to visualize relationships between groups of human genes and existing cancer treatments. 
  •  
  • The unsupervised approach makes ENLIGHT|Lens scalable and effective in situations where large training cohorts aren’t available, as is the case in most drug development scenarios.

ENLIGHT|Match: Patient-specific predictive cancer care

  •  
  • Our proprietary ENLIGHT Matching Score (EMS) enables oncologists to identify a treatment’s efficacy potential for each individual patient, for multiple cancer types.
  •  
  • The approach used by ENLIGHT|Match has been validated in a retrospective analysis of 1,000+ patients who received immunotherapy or targeted therapy, which demonstrated that a high EMS is associated with a significantly better response to treatment. 

Future-ready collaborations

Pangea is currently collaborating with clinicians and researchers from some of the world's leading institutes. Our research collaborations leverage our ENLIGHT platform to study disease mechanisms, extending ENLIGHT|Match by incorporating novel sequencing technologies such as single-cell sequencing and blood-based tumor analysis. 

Pharma and biotech partners use ENLIGHT|Lens to improve clinical programs, and our work with NGS labs helps develop and validate novel transcriptomic and multi-omic biomarkers.

Our Publications

Our publications reflect the latest developments and findings at the intersection of precision oncology and artificial intelligence, as well as our commitment to promoting research for the benefit of those battling cancer.

News

May 2022
Pangea appoints Dr. Ezra Cohen as Chairman of its Scientific Advisory Board

Dr. Cohen will lead Pangea's SAB as the company identifies the most impactful applications of ENLIGHT.

March 2022
Preprint of Pangea-led collaboration now on bioRxiv

Showcasing ENLIGHT's ability to improve both personalized oncology and clinical trial design

November 2021
Professor J. Silvio Gutkind joins Pangea’s Scientific Advisory Board

Leading researcher and NAM member to contribute to Pangea

About

Our Company DNA ...and RNA

Founded in 2018, Pangea Biomed developed the world’s most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, we are mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world. 

Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development, and empower oncologists to treat patients with success.

Our company DNA is determination, collaboration, and an insatiable thirst for innovation.

Our company RNA is our researchers, executive team, and employees – who bring our message to the world.

Eytan Ruppin, MD, PhD

Co-Founder

Ze’ev Ronai, PhD

Co-Founder

Eyal Gottlieb, MD, PhD

Co-Founder

Raanan Berger, MD, PhD

SAB Member

Ezra Cohen, MD, FRCPSC, FASCO

SAB Member

Dan A. Landau, MD, PhD

SAB Member

Tuvik Beker, PhD

CEO & Board Member

Ranit Aharonov, PhD

CTO

Emmanuel Elalouf, Pharm.D, MBA

COO

Eyal Schiff, MD

Chairman

Omri Amirav-Drory, PhD

Board Member

Eytan M. Stibbe

Board Member

J. Silvio Gutkind, PhD

SAB Member

Gideon Rechavi, MD, PhD

SAB Member

Keith T. Flaherty, MD

Scientific Advisor